Eyedeal Selected for KPMG China’s Second Annual “Biotech Innovation 50” List

On April 7, the KPMG China 2nd Biotech Innovation 50 Awards Ceremony was held simultaneously in Beijing, Shanghai, and Shenzhen. Xi’an Eyedeal Medical Technology Co., Ltd. stood out among numerous contenders and was successfully selected for the list, thanks to its outstanding performance in materials innovation and product development in the field of ophthalmology.

Eyedeal holds a global patent for a new generation of medical-grade polymer material, cross-linked polyisobutylene (xPIB), invented by the company’s Chief Scientific Advisor, Dr. Len Pinchuk. The clinical trial enrollment in China for its xPIB intraocular lens has now been completed.

The selection process, jointly conducted by KPMG China, professional institutions, and industry experts, took five months to complete. Companies were evaluated across five core dimensions: technological and product leadership, background of the core management and R&D teams, capital market activity, product pipeline richness, and financial health. Eyedeal’s inclusion in the final list reflects high recognition from the evaluators and the market for its innovative technologies and achievements.